Toogood, Peter L.
Pfizer (United States)
3 papers on CoChatORCID 0000-0002-8938-6960
Most cited papers
- Verified
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics
Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies
Cited by 1,236
- Verified
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry
Heterocyclic Compound Synthesis and BioactivityAdvanced Breast Cancer Therapies
Cited by 513
- Verified
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research
Multiple Myeloma Research and TreatmentsCancer-related Molecular Pathways
Cited by 225
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free